Do patients with type 2 diabetes on peritoneal dialysis need less insulin if they are given rosiglitazone?
Werner A Scherbaum
Correspondence Department of Endocrinology, Diabetes and Rheumatology, University Hospital Düsseldorf and German Diabetes Center, Leibniz Center for Diabetes Research, Auf'm Hennekamp 65, D-40225 Düsseldorf, Germany
Email scherbaum@ddz.uni-duesseldorf.de
This article has no abstract so we have provided the first paragraph of the full text.
Patients with end-stage renal disease (ESRD) and diabetes have a poor survival prognosis.1, 2 Among other factors, survival of these individuals is influenced by the quality of glycemic control,2 which is itself best reflected by HbA1c level. There are no good data, however, to indicate that the dose of insulin required by diabetic ESRD patients correlates with the outcome of these patients. Furthermore, in spite of experimental indications, insulin resistance is not a clinical problem in patients with type 2 diabetes and ESRD. In view of these facts, the clinical relevance of determining insulin dose as a primary outcome measure in patients with type 2 diabetes and ESRD is not evident.
Full text of this article is available with one of the following:
- Membership of the International Society of Nephrology. If already a member, please login. If not please join the Society now
- Personal subscription Purchase your own personal subscription to this journal. Already a subscriber? Please login for immediate access.
- 7 day single article pass for US$18 In order to purchase this article you must be a registered user. Please register or login above.
- Site licence Learn more about institutional site licences
Current Subscribers
Please log in to access the full text article using the login box at the top of the page.
